Baird analyst Eric Coldwell downgrades $Medpace (MEDP.US)$ to a hold rating, and adjusts the target price from $413 to $349.
According to TipRanks data, the analyst has a success rate of 53.2% and a total average return of 4.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Medpace (MEDP.US)$'s main analysts recently are as follows:
The company anticipates that cancellations from the first through the third quarter will continue, potentially impacting the book-to-bill from the fourth quarter of 2024 to the second quarter of 2025. This situation might make a return to a 1.2x book-to-bill ratio unlikely until the second half of 2025 at the earliest.
It is anticipated that Medpace may not experience significant multiple expansion due to the low net new business, with a potential decline in revenue growth by 2025. Nonetheless, the company's current cancellation issues are expected to be temporary and could lead to a robust reacceleration in 2026.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
